Altimmune Inc (NAS:ALT)
$ 8.57 -0.16 (-1.83%) Market Cap: 609.54 Mil Enterprise Value: 471.93 Mil PE Ratio: 0 PB Ratio: 4.57 GF Score: 30/100

Altimmune Inc to Host Key Opinion Leader Call on Pemvidutide Phase 1 Clinical Trial Results - Conference Call Transcript

Sep 30, 2021 / 01:00PM GMT
Release Date Price: $11.31 (-11.36%)
Operator

Greetings, and welcome to the Altimmune, Inc. Key Opinion Leader call on pemvidutide under development for obesity and NASH. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Will Brown, Chief Financial Officer. Thank you. You may begin.

William Michael Brown
Altimmune, Inc. - CFO & Principal Accounting Officer

Thank you, operator, and thank you, everyone, for participating in today's Key Opinion Leader call on the previously announced results of our 12-week Phase 1 clinical trial of pemvidutide in overweight and obese subjects. Leading the call today will be Dr. Scott Harris, Chief Medical Officer of Altimmune, along with Dr. Stephen Harrison, Key Opinion Leader. After the prepared remarks, we will open up the call for a Q&A session. As a reminder, this conference call is being recorded and will be available for audio rebroadcast on Altimmune's website at www.altimmune.com. Please click the webcast link on our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot